Takeda Pharmaceutical, Japan’s largest drugmaker, is scouting for potential multibillion-dollar acquisitions in the United States and other overseas markets as it seeks to reduce its dependence on domestic sales, which are proving sluggish.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com